- Home
- BCDA vs HIHO Comparison
BCDA vs HIHO Comparison
Compare BCDA & HIHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- HIHO
- Stock Information
- Founded
- BCDA N/A
- HIHO 1990
- Country
- BCDA United States
- HIHO Hong Kong
- Employees
- BCDA N/A
- HIHO N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- HIHO Industrial Machinery/Components
- Sector
- BCDA Health Care
- HIHO Industrials
- Exchange
- BCDA Nasdaq
- HIHO Nasdaq
- Market Cap
- BCDA 11.3M
- HIHO 7.6M
- IPO Year
- BCDA N/A
- HIHO 1996
- Fundamental
- Price
- BCDA $2.15
- HIHO $1.67
- Analyst Decision
- BCDA Strong Buy
- HIHO
- Analyst Count
- BCDA 1
- HIHO 0
- Target Price
- BCDA $25.00
- HIHO N/A
- AVG Volume (30 Days)
- BCDA 42.7K
- HIHO 196.5K
- Earning Date
- BCDA 11-12-2025
- HIHO 09-11-2025
- Dividend Yield
- BCDA N/A
- HIHO 6.82%
- EPS Growth
- BCDA N/A
- HIHO N/A
- EPS
- BCDA N/A
- HIHO 0.01
- Revenue
- BCDA N/A
- HIHO $7,080,000.00
- Revenue This Year
- BCDA N/A
- HIHO N/A
- Revenue Next Year
- BCDA N/A
- HIHO N/A
- P/E Ratio
- BCDA N/A
- HIHO $182.23
- Revenue Growth
- BCDA N/A
- HIHO 3.31
- 52 Week Low
- BCDA $1.63
- HIHO $1.40
- 52 Week High
- BCDA $3.26
- HIHO $2.88
- Technical
- Relative Strength Index (RSI)
- BCDA 58.42
- HIHO 48.69
- Support Level
- BCDA $2.11
- HIHO $1.59
- Resistance Level
- BCDA $2.29
- HIHO $1.83
- Average True Range (ATR)
- BCDA 0.08
- HIHO 0.09
- MACD
- BCDA 0.03
- HIHO 0.00
- Stochastic Oscillator
- BCDA 64.10
- HIHO 22.36
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About HIHO Highway Holdings Limited
Highway Holdings Ltd is a holding company. Along with its subsidiaries, it operates as a fully integrated manufacturer of high-quality metal, plastic, electric and electronic components, subassemblies, and finished products for OEMs and contract manufacturers. The manufacturing services offered by the group include metal stamping, screen printing, plastic injection molding, pad printing, and electronic assembly of printed circuit boards. Its reportable business segments are metal stamping and mechanical OEM operations, which derive maximum revenue, and electric OEM operations. Geographically, the group generates maximum revenue from Europe, and the rest from North America, Hong Kong and China, and other Asian countries.